Merus (MRUS) Competitors $46.58 -3.08 (-6.20%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MRUS vs. RDY, PCVX, SRPT, CTLT, RVMD, QGEN, ITCI, ROIV, ASND, and LEGNShould you be buying Merus stock or one of its competitors? The main competitors of Merus include Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Catalent (CTLT), Revolution Medicines (RVMD), Qiagen (QGEN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Merus vs. Dr. Reddy's Laboratories Vaxcyte Sarepta Therapeutics Catalent Revolution Medicines Qiagen Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Legend Biotech Dr. Reddy's Laboratories (NYSE:RDY) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, community ranking, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment. Which has stronger valuation & earnings, RDY or MRUS? Dr. Reddy's Laboratories has higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$299.87B0.04$668M$0.6322.49Merus$43.95M72.56-$154.94M-$3.95-11.79 Does the media refer more to RDY or MRUS? In the previous week, Dr. Reddy's Laboratories had 1 more articles in the media than Merus. MarketBeat recorded 4 mentions for Dr. Reddy's Laboratories and 3 mentions for Merus. Merus' average media sentiment score of 1.38 beat Dr. Reddy's Laboratories' score of -0.32 indicating that Merus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Merus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate RDY or MRUS? Dr. Reddy's Laboratories currently has a consensus price target of $17.00, indicating a potential upside of 19.97%. Merus has a consensus price target of $86.70, indicating a potential upside of 86.13%. Given Merus' stronger consensus rating and higher probable upside, analysts plainly believe Merus is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Merus 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.15 Which has more volatility and risk, RDY or MRUS? Dr. Reddy's Laboratories has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Merus has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Do institutionals & insiders hold more shares of RDY or MRUS? 14.0% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 96.1% of Merus shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 4.6% of Merus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in RDY or MRUS? Merus received 25 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 66.67% of users gave Merus an outperform vote while only 59.55% of users gave Dr. Reddy's Laboratories an outperform vote. CompanyUnderperformOutperformDr. Reddy's LaboratoriesOutperform Votes32159.55% Underperform Votes21840.45% MerusOutperform Votes34666.67% Underperform Votes17333.33% Is RDY or MRUS more profitable? Dr. Reddy's Laboratories has a net margin of 17.81% compared to Merus' net margin of -680.61%. Dr. Reddy's Laboratories' return on equity of 18.53% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories17.81% 18.53% 13.01% Merus -680.61%-38.89%-31.16% SummaryMerus beats Dr. Reddy's Laboratories on 11 of the 19 factors compared between the two stocks. Ad Investors AlleyStrange: Why is Amazon suddenly yielding 39.70%?Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%!Click here to see this breakthrough before everyone else → Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRUS vs. The Competition Export to ExcelMetricMerusPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.19B$6.39B$5.07B$8.66BDividend YieldN/A8.08%5.10%4.06%P/E Ratio-11.7910.92101.9117.46Price / Sales72.56244.561,195.1369.04Price / CashN/A53.4941.0436.36Price / Book4.549.306.345.87Net Income-$154.94M$154.14M$119.64M$225.66M7 Day Performance-14.53%-9.47%-5.13%-1.34%1 Month Performance-9.97%-7.30%-2.72%1.15%1 Year Performance91.69%28.21%31.10%24.02% Merus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRUSMerus1.88 of 5 stars$46.58-6.2%$86.70+86.1%+95.7%$3.19B$43.95M-11.7937Positive NewsRDYDr. Reddy's Laboratories1.3454 of 5 stars$14.56-1.4%N/A+6.7%$12.15B$3.35B23.2627,048Analyst DowngradeShort Interest ↑PCVXVaxcyte3.3295 of 5 stars$96.63-2.8%N/A+73.3%$12.04BN/A-21.01160News CoverageHigh Trading VolumeSRPTSarepta Therapeutics4.9455 of 5 stars$112.48-1.6%N/A+26.0%$10.74B$1.24B89.981,314Analyst UpgradeCTLTCatalent2.8783 of 5 stars$59.15-0.2%N/A+48.7%$10.74B$4.42B-26.1716,900Analyst UpgradeInsider SellingNews CoverageRVMDRevolution Medicines3.5548 of 5 stars$58.13-2.0%N/A+159.4%$9.78B$11.58M-16.19443QGENQiagen4.2892 of 5 stars$42.63-1.4%N/A+1.6%$9.73B$1.97B109.315,967Analyst RevisionITCIIntra-Cellular Therapies4.5093 of 5 stars$88.22-0.3%N/A+51.6%$9.35B$464.37M-101.40560Insider SellingPositive NewsROIVRoivant Sciences3.419 of 5 stars$11.95+2.7%N/A+24.2%$8.84B$124.79M2.12860Analyst ForecastNews CoverageASNDAscendis Pharma A/S3.0537 of 5 stars$126.03-1.3%N/A+35.3%$7.64B$288.08M-13.54640Analyst DowngradeShort Interest ↑News CoverageGap DownLEGNLegend Biotech1.8575 of 5 stars$39.35-2.1%N/A-39.9%$7.17B$285.14M-41.421,800Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews Coverage Related Companies and Tools Related Companies Dr. Reddy's Laboratories Competitors Vaxcyte Competitors Sarepta Therapeutics Competitors Catalent Competitors Revolution Medicines Competitors Qiagen Competitors Intra-Cellular Therapies Competitors Roivant Sciences Competitors Ascendis Pharma A/S Competitors Legend Biotech Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MRUS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
